The chemical structure of tepotinib and its anti-tumor mechanism

Tepotinib, also known asTepotinib, is a drug with a specific chemical structure. Its structural formula is:N-((R)-1-(3,5-Dichlorophenyl span>)ethyl)-1-methyl-6-(7-(tetrahydro- 2H-pyran-4-yl)imidazo[1,2-b][1,2,4]Triazine-2-yl)-1H-indazole-4-carboxamide. The molecular formula of this drug is C29H28Cl2N6O2, and its molecular weight reaches 563.49 g/mol.

The molecular structure of Tepotinib is very unique and contains several key components: a 3,5-dichlorophenyl ring, which enhances the drug’s targeting ability; an indazole ring, which is the core of the drug’s tyrosine kinase inhibitory effect; a unique 7-Substituted imidazo[1,2-b][1,2,4]triazine ring, which provides it with special pharmacological effects; and a tetrahydro-2H-pyran group, which helps improve the bioavailability and stability of the drug.

This special chemical structure enables Tepotinib to accurately bind and inhibit the tyrosine kinase activity ofMET receptors. More specifically, the indazole and triazine ring structures in the drug interact with the ATP binding site of the MET receptor, thereby blocking its phosphorylation process. Such a mechanism effectively inhibits the MET signaling pathway, thereby preventing further growth and spread of tumor cells.

The design of Tepotinib is based on in-depth research onMETreceptor tyrosine kinase. WhereasMETThe receptor is abnormally expressed or mutated in many cancers. Tepotinib significantly slows down the development of tumors by precisely blocking its activity. The optimized configuration of multiple substituents in its chemical structure further improves the targeting and therapeutic effect of the drug.

In general, the complex structure and specific design of tepotinib make it an effective drug that inhibits the activity ofMET receptor tyrosine kinase. The phenyl, indazole, triazine ring and tetrahydropyran parts in its structure together provide strong support for the treatment of metastatic non-small cell lung cancer (NSCLC) carrying METexon14 skipping mutations.